Payment overview · 2025
General Payments
$974.92
66 reported records · 19 companies
Healthcare provider profile · identity verified
Brian T Cady, MD
Allopathic & Osteopathic Physicians|Family Medicine · MOLINE, IL · NPI 1083619134
Verified facts
What the public records show
CMS Open Payments records show Brian T Cady, MD received $974.92 in general payments during 2025 across 66 reported records.
ABBVIE INC. accounted for 21.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic, Rexulti, Synthroid, Trelegy Ellipta, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 249 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EUCRISA as an associated drug or biological on 1712 records involving 991 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Eucrisa by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Paxlovid by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $211.26 | 21.7% | 20 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $162.44 | 16.7% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $90.53 | 9.3% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $79.16 | 8.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $56.39 | 5.8% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $49.89 | 5.1% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $43.02 | 4.4% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.71 | 4.1% | 5 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $34.91 | 3.6% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $34.65 | 3.5% | 2 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $26.37 | 2.7% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $23.28 | 2.4% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $22.62 | 2.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.14 | 2.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $18.70 | 1.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.12 | 1.9% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.26 | 1.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.17 | 1.6% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $14.30 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $974.92 | 66 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $162.44 | 13 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $118.68 | 12 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $118.29 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $100.38 | 10 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $85.81 | 7 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $79.16 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $56.39 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $49.89 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $43.02 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $39.71 | 5 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $34.91 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $34.65 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $33.29 | 3 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $26.37 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $23.28 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $22.62 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.12 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.26 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $15.17 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $14.82 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $14.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 249 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 122 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 85 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 44 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 111 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
39 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
44 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
111 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
122 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
76 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
85 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
119 | 30 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
249 | 46 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | EUCRISA open payments reported associated product |
CMS Open Payments — General Payments 1712 supporting records · 991 recipient NPIs · example record 1228794851 |
Eucrisa · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
58 | 58 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 733 | 205 |
| Atorvastatin Calcium | Atorvastatin Calcium | 714 | 190 |
| Levothyroxine Sodium | Levothyroxine Sodium | 696 | 168 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 544 | 153 |
| Amlodipine Besylate | Amlodipine Besylate | 514 | 153 |
| Pantoprazole Sodium | Pantoprazole Sodium | 474 | 135 |
| Losartan Potassium | Losartan Potassium | 421 | 117 |
| Sertraline Hcl | Sertraline Hcl | 348 | 80 |
| Metoprolol Succinate | Metoprolol Succinate | 345 | 93 |
| Gabapentin | Gabapentin | 333 | 80 |
| Tramadol Hcl | Tramadol Hcl | 333 | 97 |
| Fluticasone Propionate | Fluticasone Propionate | 309 | 131 |
| Omeprazole | Omeprazole | 280 | 67 |
| Metformin Hcl | Metformin Hcl | 278 | 81 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 276 | 68 |
| Alprazolam | Alprazolam | 274 | 67 |
| Simvastatin | Simvastatin | 256 | 71 |
| Eliquis | Apixaban | 249 | 46 |
| Clonazepam | Clonazepam | 220 | 42 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 213 | 51 |
| Alendronate Sodium | Alendronate Sodium | 209 | 70 |
| Furosemide | Furosemide | 208 | 72 |
| Montelukast Sodium | Montelukast Sodium | 190 | 48 |
| Azelastine Hcl | Azelastine Hcl | 188 | 69 |
| Trazodone Hcl | Trazodone Hcl | 185 | 52 |
| Meloxicam | Meloxicam | 184 | 40 |
| Methylprednisolone | Methylprednisolone | 175 | 140 |
| Tamsulosin Hcl | Tamsulosin Hcl | 174 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 160 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 157 | 41 |
| Baclofen | Baclofen | 148 | 50 |
| Metformin Hcl Er | Metformin Hcl | 147 | 45 |
| Finasteride | Finasteride | 146 | 40 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 146 | 42 |
| Flunisolide | Flunisolide | 143 | 70 |
| Carvedilol | Carvedilol | 142 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 140 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 140 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 138 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 138 | 44 |
| Potassium Chloride | Potassium Chloride | 136 | 48 |
| Fenofibrate | Fenofibrate | 134 | 37 |
| Famotidine | Famotidine | 132 | 34 |
| Doxycycline Hyclate | Doxycycline Hyclate | 129 | 110 |
| Atenolol | Atenolol | 128 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 128 | 39 |
| Citalopram Hbr | Citalopram Hydrobromide | 124 | 27 |
| Jardiance | Empagliflozin | 122 | 32 |
| Memantine Hcl | Memantine Hcl | 122 | 24 |
| Rybelsus | Semaglutide | 119 | 30 |
| Januvia | Sitagliptin Phosphate | 114 | 23 |
| Allopurinol | Allopurinol | 112 | 33 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 111 | 21 |
| Lorazepam | Lorazepam | 110 | 34 |
| Ezetimibe | Ezetimibe | 103 | 32 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 102 | 82 |
| Donepezil Hcl | Donepezil Hcl | 100 | 28 |
| Azithromycin | Azithromycin | 96 | 86 |
| Glimepiride | Glimepiride | 96 | 29 |
| Pioglitazone Hcl | Pioglitazone Hcl | 95 | 29 |
| Ipratropium Bromide | Ipratropium Bromide | 94 | 42 |
| Bupropion Xl | Bupropion Hcl | 92 | 33 |
| Prednisone | Prednisone | 92 | 68 |
| Buspirone Hcl | Buspirone Hcl | 89 | 23 |
| Ondansetron Odt | Ondansetron | 86 | 53 |
| Ozempic | Semaglutide | 85 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 83 | 26 |
| Mounjaro | Tirzepatide | 76 | 12 |
| Warfarin Sodium | Warfarin Sodium | 75 | 17 |
| Spironolactone | Spironolactone | 74 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 72 | 15 |
| Cefdinir | Cefdinir | 71 | 51 |
| Doxazosin Mesylate | Doxazosin Mesylate | 70 | 16 |
| Ibuprofen | Ibuprofen | 70 | 23 |
| Nabumetone | Nabumetone | 70 | 29 |
| Sulindac | Sulindac | 67 | 24 |
| Terazosin Hcl | Terazosin Hcl | 67 | 19 |
| Pregabalin | Pregabalin | 66 | 26 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 64 | suppressed |
| Gemfibrozil | Gemfibrozil | 61 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 61 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 61 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | 17 |
| Paxlovid | Nirmatrelvir/Ritonavir | 58 | 58 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 16 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 53 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 53 | 12 |
| Telmisartan | Telmisartan | 53 | 14 |
| Belsomra | Suvorexant | 49 | 13 |
| Xarelto | Rivaroxaban | 49 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 48 | 45 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 48 | 11 |
| Irbesartan | Irbesartan | 47 | 12 |
| Myrbetriq | Mirabegron | 47 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | 13 |
| Invokana | Canagliflozin | 44 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 44 | suppressed |
| Synthroid | Levothyroxine Sodium | 44 | 12 |
| Roflumilast | Roflumilast | 43 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 30 |
| Farxiga | Dapagliflozin Propanediol | 41 | suppressed |
| Repatha Sureclick | Evolocumab | 41 | suppressed |
| Tradjenta | Linagliptin | 41 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 40 | 15 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 40 | 19 |
| Bydureon Bcise | Exenatide Microspheres | 39 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 39 | 12 |
| Linzess | Linaclotide | 39 | 17 |
| Nitroglycerin | Nitroglycerin | 39 | 28 |
| Valsartan | Valsartan | 39 | suppressed |
| Fluocinonide | Fluocinonide | 38 | 28 |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 38 | suppressed |
| Lovastatin | Lovastatin | 37 | suppressed |
| Mirtazapine | Mirtazapine | 37 | suppressed |
| Rexulti | Brexpiprazole | 37 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 37 | 15 |
| Chlorthalidone | Chlorthalidone | 36 | 14 |
| Felodipine Er | Felodipine | 36 | 11 |
| Oxaprozin | Oxaprozin | 36 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 33 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 33 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 32 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 31 | 18 |
| Repatha Syringe | Evolocumab | 31 | suppressed |
| Celecoxib | Celecoxib | 30 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Diazepam | Diazepam | 28 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 28 | suppressed |
| Lansoprazole | Lansoprazole | 28 | suppressed |
| Primidone | Primidone | 28 | suppressed |
| Lamotrigine | Lamotrigine | 27 | suppressed |
| Olanzapine | Olanzapine | 27 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 26 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 18 |
| Tresiba Flextouch U-200 | Insulin Degludec | 25 | suppressed |
| Carbamazepine | Carbamazepine | 24 | suppressed |
| Nexletol | Bempedoic Acid | 24 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 23 | suppressed |
| Lubiprostone | Lubiprostone | 23 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | 20 |
| Oxcarbazepine | Oxcarbazepine | 22 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 13 |
| Desloratadine | Desloratadine | 21 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 21 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 14 |
| Raloxifene Hcl | Raloxifene Hcl | 20 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Nateglinide | Nateglinide | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 14 |
| Nystatin | Nystatin | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Premarin | Estrogens, Conjugated | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 12 |
| Rivastigmine | Rivastigmine | 17 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 17 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 17 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Klayesta | Nystatin | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Verapamil Sr | Verapamil Hcl | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | 15 |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Tadalafil | Tadalafil | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 14 | suppressed |
| Niacin Er | Niacin | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Eucrisa | Crisaborole | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Mirabegron Er | Mirabegron | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Acarbose | Acarbose | 11 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Emgality Syringe | Galcanezumab-Gnlm | 11 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 11 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 11 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $974.92 · 66 records | ABBVIE INC. | Auvelity, Cologuard Collection Kit, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, LEQVIO, LOREEV XR, Leqembi, NURTEC ODT, Ohtuvayre, Ozempic, QULIPTA, REXULTI, SYNTHROID, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VOQUEZNA, VRAYLAR, WATCHMAN Access System, ZAVZPRET, ZORYVE | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error